

Your specialist in oral liquid medicines



ROSEMONT PHARMACEUTICALS

With more than 50 years experience and an extensive range of both licensed products and specials, within the UK we are the experts in liquid medicines, delivering effective medicines management solutions for patients with swallowing difficulties.

Rosemont are highly respected in the industry and have been instrumental in establishing best practice for the care of such patients. At our state of the art production facility in the UK, we manufacture in excess of 1 million litres of bulk liquid equating to 4 million bottles of liquid medicines per year.

Perrigo[®]

Rosemont Pharmaceuticals are part of Perrigo Company plc, one of the world's leading selfcare companies, with upwards of 10,000 employees and more than \$4 billion annual sales from over 18,000 products.



ROSEMONT'S MISSION & CORE VALUES

Our mission is to improve the health, quality of life and wellbeing of vulnerable patients through the development, manufacture and supply of high quality prescription oral liquid medicines.



We are committed to the pursuit of excellence in everything we do. All of our medicines – both licensed and specials are batch manufactured in compliance with good manufacturing practice (GMP).



We have an open and ethical approach to our business practices. Published price lists are available for both UK licensed and special medicines. We believe that transparency is key to building the trust of our stakeholders.



We listen to our customers and respond to their needs through a continual programme of new product development.



We take our responsibility to stakeholders very seriously and put this commitment at the core of everything we do.

A LEADER IN LIQUID MEDICINES

THE FUTURE

We currently have an extensive range of over 70 UK licensed liquid medicines and will continue to invest in R&D, our site technology, capabilities and capacity.

Reasonably Priced Pharmaceuticals (RP)

The company we know today began life over 50 years ago, set up by two far-sighted pharmacists from Leeds in response to patients who often asked them for oral liquid medicines – which they struggled to source.



110,000 Bottles Donated to Band Aid

We made a charity donation of liquid medication to the Band Aid appeal for the African relief effort.



Site Expansion

£6 million was invested to support site expansion. The additional units included a new warehouse and production facilities. This significantly improved our factory throughput.



Perrigo plc

Rosemont became part of Perrigo plc, a leading global selfcare supplier.







2009





1985



2006



filling line for greater

accuracy.



FMD Compliant

Rosemont have invested £2.4 million over 3 years to successfully implement FMD.

First Licensed Product

Our first marketing authorisation license was granted 30th October 1974 for Folic Acid 2.5mg/5ml Oral Solution. Since then, we have continued to invest in product development.



Akzo Nobel

With the change in ownership, the name of our company then became Rosemont Pharmaceuticals.

A GLOBAL PRESENCE BUILT ON STRONG PARTNERSHIPS

Rosemont products are exported to over 30 countries worldwide. Our ongoing commitment to research and development means we are continually striving to provide more oral liquid products to the market, helping patients who are suffering from swallowing difficulties.

Our aim is to build on this momentum, by expanding our distribution, wholesale and manufacturing partnerships.

Rosemont are a trusted name in liquid medicines and we hold strong brand equity in the UK market. Our proven presence is reinforced by decades of consistent and relevant communications to UK healthcare professionals across multi-channel platforms - including an on-line resource that delivers easy access to educational materials, product information and up-to-date price lists.

We understand your requirements; our customer support team and dedicated account managers process your requests for quotations efficiently and in a responsive way to meet your time-lines. But our support doesn't stop there. We know that building and sustaining relationships is critical, in the UK we provide helpful tools such as educational materials and technical specifications to enhance sales opportunities.



SWALLOWING DIFFICULTIES

Swallowing difficulties are a global problem. Total figures are difficult to assess but it is thought that around 99 million people worldwide are sufferers¹, with 15 million in the USA alone². The issue is prevalent or is a key concern in stroke patients, patients with dementia, patients with head and neck cancer³, and people with intellectual disabilities⁴.



People experiencing swallowing difficulties can be unable to take solid dose tablets or capsules as prescribed and this often results in manipulation of the medication by crushing tablets or opening capsules⁵. In a study where patients over the age of 65 were asked if they had problems swallowing medication, 62% had experienced difficulty in swallowing solid dose medication at some time, 58% crushed tablets or opened capsules to aid administration of medication, and 68% of them said that they would not tell their doctor or pharmacist if they were unable to swallow their tablets⁶.

Crushing tablets can have unintended effects. If a modified release medication is crushed, it may result in an initial overdose of the medicine, followed by a period of under-dosing⁷. Mixing medication with food or drink may affect bioavailability⁸ but other factors like absorption, incompatibility and interactions also need to be considered⁹. That changed bioavailability may also be accompanied by increased risk of side effects¹⁰. In care homes, one of the most common medication errors is a consequence of crushing tablets¹⁰. Where patients have a PEG tube, up to 45% can become clogged or blocked, one of the reasons for this can be crushed medication¹¹⁻¹³.

Licensed liquid medicines can provide an easy to swallow, more appropriate formulation for patients with swallowing difficulties⁷ and are a preferred option to avoid clogged PEG tubes¹².

A SOLUTION TO THE PROBLEM

Rosemont Pharmaceuticals manufacture a portfolio of over 130 oral liquid medicines including over 70 licensed products — all made to the same exacting standards under GMP. Our UK range also includes 8 products licensed for use with PEG/NG tubes.















Our portfolio also includes a number of UK licensed liquid products for paediatric use – where excipients are kept to a minimum and palatability is important. New products are continually being developed, licensed and added to our extensive range of therapeutic categories which include the following:

- Cardiovascular System
- Central Nervous System
- Endocrine System
- Gastro-intestinal System

- Infections
- Malignant Disease & Immunosuppression
- Nutrition & Blood

RESEARCH AND DEVELOPMENT



Rosemont are committed to the pursuit of excellence in everything we do and invest heavily in research and development.

We have a team of 23 scientists at our UK R&D site who are experts in the development of liquid medicines. Our scientists have accumulated a unique bank of knowledge about 'liquid solutions' over the company's fifty year history.

We listen to our customers and respond to their needs through a continual programme of new product development. We aim to ensure that we create new formulations that patients find palatable as well as effective, and we run taste trials for all new products.

Rosemont works continuously to produce products with minimal excipients, making many of them suitable for patients of all ages with a variety of religious and dietary requirements. Despite most products already having a minimum shelf life of 9 months, we also strive to extend shelf-life for our products. Wherever possible, we look to convert specials into licensed products.

MANUFACTURING CAPABILITIES

The majority of Rosemont products are manufactured at our state-of-the-art production facility in Yorkshire, UK. Our manufacturing plant has benefitted from continual investment to future proof our business to meet our customers' ever changing needs.

A clear benefit of this investment strategy is that the capacity of our production facility has significantly increased.


- Approximately 1 million litres bulk liquid per year
- Batch size ranges from 10L 10,000L
- Approximately 75% of products are solutions and 25% are suspensions.
- Bottle sizes range from 30ml 500ml
- We fill approximately 4.5 million bottles per year
- We process over 800 orders per week.

Falsified Medicines Directive (FMD)

Rosemont have made significant financial investment in infrastructure changes, IT software upgrades, regulatory submissions and new site processes as well as robust trials and testing to ensure the smooth transition to FMD compliance.

Our facility is fully FMD compliant. We now apply the following safety features to each pack:

- 1. A unique 2D barcode (containing a randomised serial number).
- 2. A manufacturer selected tamper evident seal.



QUALITY CONTROL AND STANDARDS

Our quality control (QC) team conduct physical, chemical and microbiological testing to verify stability for all our licensed and unlicensed products.

The QC team also provide analytical support to quality assurance and support the production facility with purified water testing, environmental monitoring and in process controls.

We adhere to Good Manufacturing Practice (GMP) and International Conference on Harmonisation (ICH) Q10 quality control guidelines. Our manufacturing facilities are also regularly inspected and approved by both the UK and US pharmaceutical regulatory agencies. Additional approvals come from the many healthcare institutions, customers and companies that are purchasing Rosemont liquids around the world.



At Rosemont we adhere to and comply with the following standards:



Inspected for compliance by UK and US Authorities:

- UK MHRA
- US FDA
- External Customers

Key certifications:

- GMP Certificate/Manufacturing Licensed Products
- MHRA and FDA approved site
- Manufacturer 'Specials' License
- Category 4 and cytotoxic products produced

UK pharmaceutical licenses:

- Manufacturer/Importer License (MIA 427)
- Manufacturer 'Specials' License (MS 427)
- Wholesaler/Dealer License (WL 427)
- Investigational Medicinal Products License (IMP 427)

OUTSTANDING SUPPORT SERVICES

The support services Rosemont offer to healthcare professionals in the UK include:

Rosemont Website



- www.rosemontpharma.com
- Full product specs, SPCs and patient information leaflets
- Certificates of Analysis for specials
- Educational resources for HCPs
- Publications for download
- Price lists

Rosemont App



- Free to download from your chosen app store
- Complete product detail reference guide
- Unique liquid medicine dosage calculator
- Medication management information

Marketing Support



- Regular campaigns, raising awareness of swallowing difficulties and liquid medicines format
- New product launch support across both print and digital channels

REFERENCES

- 1. Sherrington E. Dysphagia. Understanding thickeners, thickened fluids, texture modified foods and how to support patients. CN Vol 15, No4 September 2014. Available at https://nutrition2me.com/wp-content/uploads/2012/05/images_free-view-articles_free-downloads_dysphagia-cnsept2015.pdf Accessed August 2019
- 2. What is dysphagia? VitalStim. Accessed 13 August 2019. Available at https://www.djoglobal.com/vitalstim/patients/what-is-dysphagia
- 3. Clavé P, Shaker R. Dysphagia: current reality and scope of the problem. Nature Reviews Gastroenterology & Hepatology. 2015 May;12(5):259.
- 4. Robertson J, Chadwick D, Baines S, Emerson E, Hatton C. People with intellectual disabilities and dysphagia. Disability and rehabilitation. 2018 May 22;40(11):1345-60.
- 5. Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realise. Pharmacy in Practice, 2005
- 6. Ferguson R, Greener M. (2005) Pharmacy Magazine Vol XI, No 3 March 2005 p44.
- 7. Greenwall R. Medicine Management. Medicines management and older people a guide for healthcare professionals. Aug 2017.
- 8. Jackson. S, Naunton. M. Optimising medicine administration in patients with swallowing difficulties. Australian Pharmacist. Jan 2017.
- 9. What legal and pharmaceutical issues should be considered when administering medicines covertly? UKMI 2017
- **10.** Survey of medicines related care of residents with dysphagia in care homes. The Patients Association. https://www.patients-association.org.uk/blog/medicines-dysphagia-care-homes-residents
- 11. Fisher C, Blalock B. Clogged Feeding Tubes: A Clinician's Thorn. Nutrition Issues in Gastroenterology, Series 127. Practical Gastroenterology, March 2014.
- 12. Shragg SP, Sharma R, et al. Complications related to Percutaneous Endoscopic Gastrostomy (PEG Tubes). A comprehensive clinical review. J Gastrointestin Liver Dis. Dec 2007, Vol 16. No 4, 407-418.
- **13.** Ghevariya V, Paleti V, et al. Complications associated with percutaneous endoscopic gastrostomy tubes. Annals of long term care. Clinical Care and Aging 2009, 17 (12): 36-41.

MANUFACTURING CAPABILITIES

- Rosemont are the specialists in liquid medicines with over 50 years of experience
- Quality is our core principle
- R&D focussed on innovation
- Extensive portfolio over a range of therapy areas
- Range of products approved in the UK for PEG and NG tubes
- Experts in supporting patients with swallowing difficulties
- UK based, state of the art manufacturing facilities
- 99% service levels from customer support

For more information about Rosemont and International opportunities.

Visit our website:

www.rosemontpharma.com

Or email our team at:

international@perrigo.com

Rosemont Pharmaceuticals Ltd.

Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds LS11 9XE

T +44 (0)113 244 1400 F +44 (0)113 245 3567 E rosemont.infodesk@perrigouk.com Sales / Customer Service

T +44 (0) 113 244 1999 **F** +44 (0) 113 246 0738 www.rosemontpharma.com

DTM119 August 2019

